Truist Securities Maintains Buy on AbbVie, Raises Price Target to $215
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on AbbVie and increased the price target from $210 to $215, indicating confidence in the company's future performance.
October 10, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on AbbVie and increased the price target from $210 to $215, suggesting a positive outlook for the company's stock.
The increase in price target from $210 to $215 by Truist Securities indicates a positive sentiment towards AbbVie's future performance. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100